Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2009 1
2012 1
2013 1
2014 6
2015 20
2016 50
2017 70
2018 97
2019 110
2020 170
2021 207
2022 188
2023 166
2024 173
2025 234
2026 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV. Jhund PS, et al. Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1. Lancet. 2024. PMID: 39232490 Free article.
The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. We also estimated the effect of MRAs on components of this composite, total (first or repeat) heart failure hospitalisations (with and with …
The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. …
Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.
Legrand M, Bagshaw SM, Bhatraju PK, Bihorac A, Caniglia E, Khanna AK, Kellum JA, Koyner J, Harhay MO, Zampieri FG, Zarbock A, Chung K, Liu K, Mehta R, Pickkers P, Ryan A, Bernholz J, Dember L, Gallagher M, Rossignol P, Ostermann M. Legrand M, et al. Crit Care. 2024 Mar 21;28(1):92. doi: 10.1186/s13054-024-04877-4. Crit Care. 2024. PMID: 38515121 Free PMC article. Review.
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. ...We disc …
Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important …
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Vaduganathan M, et al. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1. Nat Med. 2024. PMID: 39218030 Free PMC article.
Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease and diabetes. ...In light of the strong epidemiological overlap and shared mechanistic drivers of clinical outcomes across cardiova …
Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease a …
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Apperloo EM, et al. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8. Lancet Diabetes Endocrinol. 2024. PMID: 38991584
The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), and hospitalisation for heart failure or cardiovascular death. ...These findings sugg …
The two main cardiovascular outcomes assessed included major adverse cardiovascular events (nonfatal myocardial infarction, no …
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.
Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Mc Causland FR, et al. J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25. J Am Coll Cardiol. 2025. PMID: 39490700 Free article. Clinical Trial.
METHODS: We explored the effects of finerenone on the secondary outcome of a sustained 50% estimated glomerular filtration rate (eGFR) decline or kidney failure (sustained eGFR decline <15 mL/min/1.73 m(2); initiation of maintenance dialysis; renal transplantation). In …
METHODS: We explored the effects of finerenone on the secondary outcome of a sustained 50% estimated glomerular filtration rate (eGFR) decli …
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD. Patel SM, et al. Circulation. 2024 Jun 4;149(23):1789-1801. doi: 10.1161/CIRCULATIONAHA.124.069568. Epub 2024 Apr 7. Circulation. 2024. PMID: 38583093 Free PMC article.
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. METHODS: This was a collaborat …
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effe …
From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition.
Zoccali C, Mallamaci F, Halimi JM, Rossignol P, Sarafidis P, De Caterina R, Giugliano R, Zannad F. Zoccali C, et al. Clin J Am Soc Nephrol. 2024 Jun 1;19(6):813-820. doi: 10.2215/CJN.0000000000000361. Epub 2023 Oct 30. Clin J Am Soc Nephrol. 2024. PMID: 37902772 Free PMC article. Review.
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascular disease and CKD, the chronic cardiovascular-kidney disorder (CCKD). This conceptual framework builds upon the fact that car …
We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascul …
Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week.
Boulestreau R, Śpiewak M, Januszewicz A, Kreutz R, Guzik TJ, Januszewicz M, Muiesan ML, Persu A, Sarafidis P, Volpe M, Zaleska-Żmijewska A, van den Born BH, Messerli FH. Boulestreau R, et al. J Am Coll Cardiol. 2024 Apr 30;83(17):1688-1701. doi: 10.1016/j.jacc.2024.02.037. J Am Coll Cardiol. 2024. PMID: 38658108 Free article. Review.
Nonadherence to the antihypertensive regimen remains the most common cause for MHT, although antiangiogenic and immunosuppressant therapy can also trigger hypertensive emergencies. Depending on the clinical presentation, parenteral or oral therapy can be used to initiate B …
Nonadherence to the antihypertensive regimen remains the most common cause for MHT, although antiangiogenic and immunosuppressant therapy ca …
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Vaduganathan M, et al. Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28. Circulation. 2025. PMID: 39340828 Free PMC article. Clinical Trial.
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity on the basis of baseline SGLT2i use. ...These data suggest that the combined use of SGLT2i and a nonst …
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed fo …
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Docherty KF, et al. Circulation. 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATIONAHA.124.072011. Epub 2024 Sep 29. Circulation. 2025. PMID: 39342512 Free PMC article. Clinical Trial.
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. RESULTS: Baseline LVEF data were available for 5993 of the 6001 participants in FINEARTS-HF. ...CONCLUSIONS: In patients with HF with mildly reduced or preserve …
The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. RESULTS: Baseline LV …
173 results